Eterna Therapeutics appoints Dorothy J. Clarke as director effective August 28, 2023

Ernexa Therapeutics Inc.

Ms. Clarke served as VP, Health Care Compliance R&D at Johnson & Johnson until November 2022.
Board determined Clarke is independent under Nasdaq rules; standard non-employee director comp applies.
No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dorothy J. Clarke

director

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-08-28
Filed: August 31, 2023, 7:59 PM ET

On August 28, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Ms. Dorothy J. Clarke as a director, effective on August 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dorothy J. Clarke was appointed as director at Ernexa Therapeutics Inc..

Action: appointed
Role: director

Exact text from the filing

On August 28, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Ms. Dorothy J. Clarke as a director, effective on August 28, 2023.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-042061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.